The following is a summary of “Global Delphi consensus on treatment goals for generalised pustular psoriasis,” published in the January 2025 issue of Dermatology by Barker et al. Generalized pustular ...

Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular PsoriasisVanda expects to immediately begin preparing ...

A team from Nagoya University in Japan has identified previously unidentified gene variants that are associated with the development of generalized pustular psoriasis (GPP). The team's findings ...

Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) and AnaptysBio, Inc. (Anaptys) (NASDAQ: ANAB) today announced an exclusive, global license agreement for the development and commercialization of imsidolimab ...

Recent studies imply that acute generalized exanthematous pustulosis ... while Th-1-derived dermatoses, such as psoriasis and sarcoidosis, are ameliorated. AGEP, a neutrophile, cell-mediated ...

This is the first approval by a regulator for Skyrizi, with the Japanese Ministry of Health Labour and Welfare granting a licence for plaque psoriasis, generalised pustular psoriasis ...

Unlike many other forms of this disease, hand and foot psoriasis is difficult to treat and often refractory to multiple therapies, even those that are effective in generalized psoriasis.